MetaVia to Present Cardiometabolic Data at ADA 2026 Scientific Sessions
Summary
MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for presentation at the American Diabetes Association's 2026 Scientific Sessions in June.
Key Events
-
Abstracts Accepted for ADA 2026
Three late-breaking abstracts highlighting MetaVia's cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for poster presentations at the American Diabetes Association's (ADA) 2026 Scientific Sessions.
-
Key Pipeline Assets Highlighted
The presentations will focus on DA-1726, a dual GLP-1/glucagon agonist for obesity, and vanoglipel (DA-1241), a GPR119 agonist for MASH and Type 2 diabetes.
-
Upcoming Conference Dates
The ADA 2026 Scientific Sessions will be held from June 5-8, 2026, in New Orleans, Louisiana.
-
Future Data Readout Expected
The company expects to report data from the DA-1726 Phase 1 Part 3 titration study in the fourth quarter of 2026.
Analysis
MetaVia announced the acceptance of three late-breaking abstracts for presentation at the American Diabetes Association's 2026 Scientific Sessions. This provides positive visibility for its key cardiometabolic assets, DA-1726 (obesity) and vanoglipel (MASH/T2D), and highlights ongoing progress in their clinical development. For a company that recently reported a going concern warning and significant dilution, any positive news regarding its pipeline is important for investor sentiment and provides a near-term catalyst with the presentations in June, and a mid-term catalyst with DA-1726 data expected in Q4 2026.
At the time of this filing, MTVA was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.97 to $19.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.